References
- 1. Brandtzaeg, P., and Prydz, H. (1984). Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 311, 71.10.1038/311071a06433206
- 2. Cines, D.B., Yasothan, U., and Kirkpatrick, P. (2008). Romiplostim. Nature Reviews Drug Discovery 7, 887.10.1038/nrd274118974747
- 3. Di Lorenzo, G., Ferro, M., and Buonerba, C. (2012). Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU International 110, E99-E104.10.1111/j.1464-410X.2011.10790.x22177289
- 4. Fong, L., Brockstedt, D., Benike, C., Breen, J.K., Strang, G., Ruegg, C.L., and Engleman, E.G. (2001). Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167, 7150-7156.10.4049/jimmunol.167.12.715011739538
- 5. Fong, L., Ruegg, C.L., Brockstedt, D., Engleman, E.G., and Laus, R. (1997). Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 159, 3113-3117.10.4049/jimmunol.159.7.3113
- 6. Fujio, K., Watanabe, M., Ueki, H., Li, S.A., Kinoshita, R., Ochiai, K., Futami, J., Watanabe, T., Nasu, Y., and Kumon, H. (2015). A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncol Rep 33, 1585-1592.10.3892/or.2015.3770435808025632844
- 7. Hiramoto, E., Tsutsumi, A., Suzuki, R., Matsuoka, S., Arai, S., Kikkawa, M., and Miyazaki, T. (2018). The IgM pen-tamer is an asymmetric pentagon with an open groove that binds the AIM protein. Science Advances 4, eaau1199.10.1126/sciadv.aau1199617937930324136
- 8. Johansen, F.E., Braathen, R., and Brandtzaeg, P. (2000). Role of J chain in secretory immunoglobulin formation. Scand J Immunol 52, 240-248.10.1046/j.1365-3083.2000.00790.x10972899
- 9. Kang, Y.J., Kim, D.-S., Myung, S.-C., and Ko, K. (2017). Expression of a Human Prostatic Acid Phosphatase (PAP)-IgM Fc Fusion Protein in Plants Using In vitro Tissue Subculture. Frontiers in Plant Science 8.10.3389/fpls.2017.00274532901628293250
- 10. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., Xu, Y., Frohlich, M.W., and Schellhammer, P.F. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363, 411-422.10.1056/NEJMoa100129420818862
- 11. Kim, K., Kang, Y.J., Park, S.R., Kim, D.-S., Lee, S.-W., Ko, K., Ponndorf, D., and Ko, K. (2021). Effect of leaf position and days post-infiltration on transient expression of colorectal cancer vaccine candidate proteins GA733-Fc and GA733-FcK in Nicotiana benthamiana plant. PeerJ 9, e10851.10.7717/peerj.10851803589933868796
- 12. Korhonen, R., and Moilanen, E. (2009). Abatacept, a Novel CD80/86–CD28 T Cell Co-stimulation Modulator, in the Treatment of Rheumatoid Arthritis. Basic & Clinical Pharmacology & Toxicology 104, 276-284.10.1111/j.1742-7843.2009.00375.x19228144
- 13. Krugmann, S., Pleass, R.J., Atkin, J.D., and Woof, J.M. (1997). Structural requirements for assembly of dimeric IgA probed by site-directed mutagenesis of J chain and a cysteine residue of the alpha-chain CH2 domain. J Immunol 159, 244-249.10.4049/jimmunol.159.1.244
- 14. Kuter, D.J., Bussel, J.B., Lyons, R.M., Pullarkat, V., Gernsheimer, T.B., Senecal, F.M., Aledort, L.M., George, J.N., Kessler, C.M., Sanz, M.A., Liebman, H.A., Slovick, F.T., De Wolf, J.T., Bourgeois, E., Guthrie, T.H., Jr., Newland, A., Wasser, J.S., Hamburg, S.I., Grande, C., Lefrere, F., Lichtin, A.E., Tarantino, M.D., Terebelo, H.R., Viallard, J.F., Cuevas, F.J., Go, R.S., Henry, D.H., Redner, R.L., Rice, L., Schipperus, M.R., Guo, D.M., and Nichol, J.L. (2008). Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371, 395-403.10.1016/S0140-6736(08)60203-218242413
- 15. Lai, T., Yang, Y., and Ng, S.K. (2013). Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel) 6, 579-603.10.3390/ph6050579381772424276168
- 16. Lim, C.-Y., Kim, D.-S., Kang, Y., Lee, Y.-R., Kim, K., Kim, M.-S., and Ko, K. (2022). Immune Responses to Plant-Derived Recombinant Colorectal Cancer Glycoprotein Ep-CAM-FcK Fusion Protein in Mice. Biomolecules & Therapeutics 30, 546-552.10.4062/biomolther.2022.103962231536263857
- 17. Linderholm, A., and Chamow, S. (2014). Immunoglobulin Fc-fusion proteins part 2: therapeutic uses and clinical development. Bioprocess Int. 2014b 12, 2-7.
- 18. Machlenkin, A., Paz, A., Haim, E.B., Goldberger, O., Finkel, E., Tirosh, B., Volovitz, I., Vadai, E., Lugassy, G., and Cytron, S. (2005). Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immuno-therapy. Cancer research 65, 6435-6442.10.1158/0008-5472.CAN-05-013316024648
- 19. Matsueda, S., Takedatsu, H., Yao, A., Tanaka, M., Noguchi, M., Itoh, K., and Harada, M. (2005). Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clinical cancer research 11, 6933-6943.10.1158/1078-0432.CCR-05-068216203785
- 20. Mcneel, D.G., Dunphy, E.J., Davies, J.G., Frye, T.P., Johnson, L.E., Staab, M.J., Horvath, D.L., Straus, J., Alberti, D., and Marnocha, R. (2009). Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. Journal of Clinical Oncology 27, 4047.10.1200/JCO.2008.19.9968273441819636017
- 21. Milstein, C.P., Richardson, N.E., Dieverson, E.V., and Feinstein, A. (1975). Interchain disulphide bridges of mouse immunoglobulin M. The Biochemical journal 151, 615-624.10.1042/bj15106151172409766753
- 22. Peshwa, M.V., Shi, J.D., Ruegg, C., Laus, R., and Van Schooten, W.C.A. (1998). Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. The Prostate 36, 129-138.10.1002/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D
- 23. Peters, R.T., Low, S.C., Kamphaus, G.D., Dumont, J.A., Amari, J.V., Lu, Q., Zarbis-Papastoitsis, G., Reidy, T.J., Merricks, E.P., Nichols, T.C., and Bitonti, A.J. (2010). Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115, 2057-2064.10.1182/blood-2009-08-239665
- 24. Powell, J.S., Josephson, N.C., Quon, D., Ragni, M.V., Cheng, G., Li, E., Jiang, H., Li, L., Dumont, J.A., Goyal, J., Zhang, X., Sommer, J., Mccue, J., Barbetti, M., Luk, A., and Pierce, G.F. (2012). Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 119, 3031-3037.10.1182/blood-2011-09-382846
- 25. Randall, T.D., Brewer, J.W., and Corley, R.B. (1992). Direct evidence that J chain regulates the polymeric structure of IgM in antibody-secreting B cells. J Biol Chem 267, 18002-18007.10.1016/S0021-9258(19)37143-1
- 26. Rasooly, R., Hernlem, B., and Friedman, M. (2013). Low levels of aflatoxin B1, ricin, and milk enhance recombinant protein production in mammalian cells. PloS one 8, e71682-e71682.10.1371/journal.pone.0071682
- 27. Roos, A.K., Pavlenko, M., Charo, J., Egevad, L., and Pisa, P. (2005). Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. The Prostate 62, 217-223.10.1002/pros.20135
- 28. Roux, K.H. (1999). Immunoglobulin structure and function as revealed by electron microscopy. Int Arch Allergy Immunol 120, 85-99.10.1159/000024226
- 29. Saif, J.M.S., Vadakekolathu, J., Rane, S.S., Mcdonald, D., Ahmad, M., Mathieu, M., Pockley, A.G., Durrant, L., Metheringham, R., Rees, R.C., and Mcardle, S.E.B. (2014). Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. European Journal of Immunology 44, 994-1004.10.1002/eji.201343863
- 30. Shanmugaraj, B.M., and Ramalingam, S. (2014). Plant expression platform for the production of recombinant pharmaceutical proteins. Austin J Biotechnol Bioeng 1, 4.
- 31. Sorensen, V., Sundvold, V., Michaelsen, T.E., and Sandlie, I. (1999). Polymerization of IgA and IgM: roles of Cys309/Cys414 and the secretory tailpiece. J Immunol 162, 3448-3455.10.4049/jimmunol.162.6.3448
- 32. Strober, B.E., and Menon, K. (2007). Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther 20, 270-276.10.1111/j.1529-8019.2007.00140.x
- 33. Vaerman, J.P., Langendries, A.E., Giffroy, D.A., Kaetzel, C.S., Fiani, C.M., Moro, I., Brandtzaeg, P., and Kobayashi, K. (1998). Antibody against the human J chain inhibits polymeric Ig receptor-mediated biliary and epithelial transport of human polymeric IgA. Eur J Immunol 28, 171-182.10.1002/(SICI)1521-4141(199801)28:01<171::AID-IMMU171>3.0.CO;2-#
- 34. Van Den Brande, J.M., Braat, H., Van Den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I., Van Montfrans, C., Hommes, D.W., Peppelenbosch, M.P., and Van Deventer, S.J. (2003). Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124, 1774-1785.10.1016/S0016-5085(03)00382-2
- 35. Wiersma, E.J., Collins, C., Fazel, S., and Shulman, M.J. (1998). Structural and functional analysis of J chain-deficient IgM. J Immunol 160, 5979-5989.10.4049/jimmunol.160.12.5979
- 36. Woof, J.M., and Russell, M.W. (2011). Structure and function relationships in IgA. Mucosal Immunol 4, 590-597.10.1038/mi.2011.39